A Physician’s Take on the CLEAR Trial Data

EP: 1.Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

EP: 2.Impressions of Data and Results from the CLEAR Trial

EP: 3.Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma: Key Takeaways

EP: 4.Incorporating Data from the CLEAR Trial into Clinical Practice

EP: 5.A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma

Now Viewing

EP: 6.A Physician’s Take on the CLEAR Trial Data

EP: 7.The Influence of Risk Category Stratification Algorithms on CLEAR Trial Data

EP: 8.Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma

EP: 9.Choosing a Combination Treatment for Advanced Renal Cell Carcinoma

EP: 10.Risk Factors in the Management of Advanced Renal Cell Carcinoma

EP: 11.Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib

EP: 12.Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment

EP: 13.Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma

EP: 14.Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma

EP: 15.Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma

EP: 16.Unmet Needs in Advanced Renal Cell Carcinoma Management

EP: 17.The Exciting Future of Advanced Renal Cell Carcinoma Management

EP: 18.Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

EP: 19.Advice for Community Oncologists Treating Renal Cell Carcinoma

EP: 20.Side Effects of IO/TKI Treatment Regimens for Renal Cell Carcinoma

EP: 21.Sequencing Strategies for Renal Cell Carcinoma Treatment Regimens

EP: 22.Cytoreductive Nephrectomies for Renal Cell Carcinoma

EP: 23.Choosing Therapies for Patients with Advanced Renal Cell Carcinoma

EP: 24.Dose Reductions and Treatment Breaks on Lenvatinib Therapy

EP: 25.Choosing a Combination Therapy for Renal Cell Carcinoma Before and After CLEAR Data

EP: 26.Treatment Approaches for Good Risk Patients with Renal Cell Carcinoma

EP: 27.Unmet Needs and the Future of Kidney Cancer

EP: 28.Recap: Implications of TKI Plus Immunotherapy Combinations for RCC

Tom Powles, MBBS, MRCP, MD: Hi, I'm Tom Powles. I'm an oncologist from London. I look after patients with urology cancers, particularly bladder and kidney cancer, which we're talking about today. Brian, would you like to introduce yourself?

Brian Shimkus, MD: Yes. I'm Brian Shimkus. I'm a physician in Austin, Texas; private practice in a multi-specialty group. I don't specialize in any particular kind of cancer, but I enjoy genitourinary cancers and work closely with a very large group close to us. I've always been fond of treating renal cell carcinoma.

Tom Powles, MBBS, MRCP, MD: Brian, we just saw Bob Watson present the CLEAR data published in New England Journal [of Medicine]. There's been a later data cut more recently. The data looked impressive, with the response rate above 70%. The hazard ratio for PFS in the 0.39, I think, and the OS survival data significant at about 0.70. The total RB profile was okay. I think these combinations are challenging to give, more challenging than the single agent therapy, certainly. What was your take on the data overall in the paper?

Brian Shimkus, MD: I think it's amazing. If you look back, I've been practicing for about 20 years and going from renal cell carcinoma as a disease with interleukin therapy as the only option to something where we have all of these options, and now can decide how we want to treat people based on side effect profiles. It really gives them a bright outcome now. I've gone from treating people with single agents to getting better at treatment with multi-agent therapy. I think that really is the key here, as I see in this study. That's one of the big take-away points, is that the better you get at this, the more experience you have with multi-agent therapy, the better your patients are going to do. It becomes critical to understand how best to use these drugs, not just knowing which drugs are available.

Transcript edited for clarity.